Aragon Pharmaceuticals Announces Acquisition by Johnson & Johnson

News   Jun 19, 2013

 
Aragon Pharmaceuticals Announces Acquisition by Johnson & Johnson
 
 
 

RELATED ARTICLES

Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”

News

The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.

READ MORE

3D Structure of DHHC Proteins Provides Blueprint for Drug Design

News

The first three-dimensional structure of DHHC proteins — enzymes involved in many cellular processes, including cancer — explains how they function and may offer a blueprint for designing therapeutic drugs.

READ MORE

Safety and Efficacy of MERS Treatment Confirmed in Phase I Trial

News

An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE